
Goals and Objectives
------------------------------------------------------------------------------------------------------
MCTA Announcement Key
Activities
------------------------------------------------------------------------------------------------------------------------
|
Goal
The goal of the Alliance
is to facilitate site preparation for the effective conduct of clinical trials
for life-saving malaria interventions and simultaneously promote the long term
development and sustainability of clinical trial sites in resource-constrained
countries in the developing world. |
|
|
Objectives Objective 1: To facilitate the development of sufficient near-term capacity in Africa to conduct GCP clinical trials for malaria vaccine and drug interventions.
The expected outcomes under this objective are as follows: a) Ensure the readiness of up to 8 sites associated with MVI RTS,S trials; and b) Ensure the readiness of 10 sites associated with MMV to test malaria drugs. (4 of these sites are involved in the MVI RTS,S trials.)
Objective 2: To support, strengthen, mentor and network trial sites to facilitate their progression toward self-sustaining clinical research centers.
The expected outcomes of this objective are as follows: a) Governance structures implemented at all trial sites that enable the sites to interact with the ministries of health, public private partnerships as well as pharmaceutical industry representatives; b) Sites have leaders who are capable of managing trials, competing for, receiving and managing funds, building research teams, and communicating with policy-makers and ministries of health; c) Well trained staff to conduct GCP vaccine and drug trials in malaria at all times; and d) Sites effectively networked to create a learning laboratory of training tools, documents, and problem solving etc to hasten their development.
KEY ACTIVITIES TO BE CARRIED OUT Activity 1: The first activity will involve the establishment of the Alliance Secretariat and staff recruitment. Activity 2: The second activity is guiding site infrastructure for the conduct of Good Clinical Practices (GCP) malaria drug and vaccine trials. Activity 3: The third activity will be promoting networking between sites. Activity 4: General GCP Training. Activity 5: General assistance to sites. Activity 6: Training for long-term sustainability.
|
|